Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 24;20(6):e0325775.
doi: 10.1371/journal.pone.0325775. eCollection 2025.

Hyperuricemia and associated factors among adult cardiovascular disease patients at Salale University Comprehensive Specialized Hospital, Fitche, Central Ethiopia

Negesse Bokona Rufe  1 , Tolera Ambisa Lamesa  2 , Aklilu Getachew Mamo  2 , Belay Merkeb Zewude  1 , Bedasa Addisu  3 , Deresa Jamma Nigusie  1 , Sintayehu Asaye Biya  2
Affiliations

Hyperuricemia and associated factors among adult cardiovascular disease patients at Salale University Comprehensive Specialized Hospital, Fitche, Central Ethiopia

Negesse Bokona Rufe et al. PLoS One. .

Abstract

Background: Despite evidence suggesting that hyperuricemia (serum uric acid >7.0 mg/dL in males and >6.0 mg/dL in females) contributes to adverse outcomes like mortality and hospitalization in patients with cardiovascular disease (CVD), a comprehensive understanding of its magnitude is still lacking, underscoring the need for further investigation. There is no previously published study about hyperuricemia in cardiovascular disease in Ethiopia. Therefore, this study aims to investigate the prevalence of hyperuricemia and its associated factors among adult patients with cardiovascular diseases at Salale University Compressive Specialized Hospital Located in Fitche, Ethiopia (115 km north of Addis Ababa),from October 1, 2023, to January 28, 2024.

Materials and methods: A hospital-based cross-sectional study was conducted on 298 participants with different types of cardiovascular disease. The participants were selected using a consecutive sampling technique. Socio-demographic factors were collected using interviewer-administered questionnaires, while overnight blood samples were collected and biochemical tests were analyzed using the COBAS c 311 automated clinical chemistry analyzer. Descriptive statistics and logistic regression analyses were performed. A variable that had a p-value of ≤ 0.05 with a 95% confidence interval was considered statistically significant.

Result: The prevalence of hyperuricemia among adult cardiovascular disease patients was 41.3% CI [35.6-47.1]. The highest prevalence of hyperuricemia was found among cardiovascular disease patients with congestive heart failure (48.0%) and hypertensive heart disease (41.2%). Factors such as physical activity (AOR: 4.1; 95% CI: 1.5-10.7, P = 0.004), dyslipidemia (AOR: 2.7; 95% CI: 1.2-6.0, P = 0.01) and chronic kidney disease (AOR: 3.1; 95% CI: 1.5-6.1, P = 0.001) were found to be associated with hyperuricemia among individuals with cardiovascular disease.

Conclusion: The study indicated a high prevalence of hyperuricemia among participants with cardiovascular disease. Physical activity, dyslipidemia, and chronic kidney disease were recognized as significant associated factors of hyperuricemia among cardiovascular disease. Therefore, early diagnosis of hyperuricemia and its management is essential to control complications and extend the life expectancy of individuals with cardiovascular disease.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Clinical factors among participants with cardiovascular diseases at SUCSH from October 1, 2023– January 28, 2024 (n = 298).
Fig 2
Fig 2. Prevalence of hyperuricemia among each cardiovascular disease types of study participants at SUCSH, from October 1, 2023– January 28, 2024, (n = 298).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Frąk W, Wojtasińska A, Lisińska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of cardiovascular diseases: new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease. Biomedicines. 2022;10(8):1938. doi: 10.3390/biomedicines10081938 - DOI - PMC - PubMed
    1. Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401. doi: 10.1186/s12889-021-10429-0 - DOI - PMC - PubMed
    1. Mengistu MD, Benti H. Assessment of magnitude and spectrum of cardiovascular disease admissions and outcomes in Saint Paul Hospital Millennium Medical College, Addis Ababa: A retrospective study, Sasso FC, editor. PLOS ONE. 2022;17(12):e0267527. doi: 10.1371/journal.pone.0267527 - DOI - PMC - PubMed
    1. Savoji H, Mohammadi MH, Rafatian N, Toroghi MK, Wang EY, Zhao Y, et al. Cardiovascular disease models: A game changing paradigm in drug discovery and screening. Biomaterials. 2019;198:3–26. doi: 10.1016/j.biomaterials.2018.09.036 - DOI - PMC - PubMed
    1. Swathy M, Saruladha K. A comparative study of classification and prediction of Cardio-Vascular Diseases (CVD) using Machine Learning and Deep Learning techniques. ICT Express. 2022;8(1):109–16. doi: 10.1016/j.icte.2021.08.021 - DOI

LinkOut - more resources